DNA methylation predicts lung function and pulmonary exacerbation in sputum samples from patients with cystic fibrosis
Abstract
Background: Lung disease is variable among patients with cystic fibrosis (CF) and depends on genetic and environmental factors. To better understand the molecular determinants of lung disease variability, we carried out an epigenome-wide association study (EWAS) in sputum samples from patients with CF. Methods: We profiled 64 sputum samples using Human Methylation EPIC BeadChips and assessed the correlation between DNA methylation levels and four clinical traits: lung function (FEV1pp), lung function variation (FEV1pp slope), presence and number of pulmonary exacerbations. Sputum samples were collected at four time points over an 18-month follow-up period. Selected CpG sites were reassessed in independent sputum samples from the same cohort by pyrosequencing. Results: In the EWAS, we identified two differentially methylated CpG sites (cg11047325/SOCS3, p = 4 × 10-6; cg18608055/SBNO2, p = 6 × 10-7) that correlated with lung function. They were validated in independent sputum samples from the same cohort using pyrosequencing. Additionally, three CpG sites (cg23107754, cg03209812 and cg09600088) split patients with declining lung function from those whose lung function either improved or remained stable (accuracy = 0.80). Of interest for CF-related diabetes, one of these CpG sites (cg09600088) maps to the BRSK2 gene, which plays a role in pancreatic beta cell function. Finally, a DNA methylation signature of 23 CpG sites predicted patients with pulmonary exacerbation (accuracy = 0.84). Conclusions: We provide the first longitudinal assessment of genome-wide DNA methylation in a cohort of patient with CF and identify CpG sites that predict clinical traits of key importance for lung disease. The associated genes play a critical role in inflammation or pancreatic endocrine activity. Overall, our results underscore the emerging role of DNA methylation as a key modulator of disease severity in CF.
Related
- DNA methylation correlates with lifespan and predicts remaining lifespan in the zebra finch
- The GPCRVP score reliably predicts the impact of GLP1R human variants on receptor function
- Intranuclear localisation of KLF3‐AS1 under the balance of histone acetylation and methylation in BMSCs ameliorates cerebral ischaemia‒reperfusion injury by preserving microglial mitochondrial function and inhibiting inflammatory polarisation
- DUF6383-domain containing protein from Parabacteroides distasonis predicts survival in patients with alcohol-associated hepatitis
- Dynamic profiles and subpopulation characteristics of extracellular vesicles in patients undergoing transcatheter pulmonary valve replacement.
BibTeX
@article{tost2026methylation,
title = {{DNA methylation predicts lung function and pulmonary exacerbation in sputum samples from patients with cystic fibrosis}},
author = {Jorg Tost and Davide Caimmi and Manuela Pastore and Christelle Reynes and Florence Busato and Fanny Pineau and Mireille Claustres and Isabelle Vachier and Raphaël Chiron and Albertina de Sario},
journal = {Clinical Epigenetics},
year = {2026},
month = oct,
doi = {10.1186/s13148-025-02032-6},
url = {https://hal.science/hal-05402062v2},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - DNA methylation predicts lung function and pulmonary exacerbation in sputum samples from patients with cystic fibrosis
AU - Jorg Tost
AU - Davide Caimmi
AU - Manuela Pastore
AU - Christelle Reynes
AU - Florence Busato
AU - Fanny Pineau
AU - Mireille Claustres
AU - Isabelle Vachier
AU - Raphaël Chiron
AU - Albertina de Sario
PY - 2026
DA - 2026/10/13
JO - Clinical Epigenetics
DO - 10.1186/s13148-025-02032-6
UR - https://hal.science/hal-05402062v2
AB - Background: Lung disease is variable among patients with cystic fibrosis (CF) and depends on genetic and environmental factors. To better understand the molecular determinants of lung disease variability, we carried out an epigenome-wide association study (EWAS) in sputum samples from patients with CF. Methods: We profiled 64 sputum samples using Human Methylation EPIC BeadChips and assessed the correlation between DNA methylation levels and four clinical traits: lung function (FEV1pp), lung function variation (FEV1pp slope), presence and number of pulmonary exacerbations. Sputum samples were collected at four time points over an 18-month follow-up period. Selected CpG sites were reassessed in independent sputum samples from the same cohort by pyrosequencing. Results: In the EWAS, we identified two differentially methylated CpG sites (cg11047325/SOCS3, p = 4 × 10-6; cg18608055/SBNO2, p = 6 × 10-7) that correlated with lung function. They were validated in independent sputum samples from the same cohort using pyrosequencing. Additionally, three CpG sites (cg23107754, cg03209812 and cg09600088) split patients with declining lung function from those whose lung function either improved or remained stable (accuracy = 0.80). Of interest for CF-related diabetes, one of these CpG sites (cg09600088) maps to the BRSK2 gene, which plays a role in pancreatic beta cell function. Finally, a DNA methylation signature of 23 CpG sites predicted patients with pulmonary exacerbation (accuracy = 0.84). Conclusions: We provide the first longitudinal assessment of genome-wide DNA methylation in a cohort of patient with CF and identify CpG sites that predict clinical traits of key importance for lung disease. The associated genes play a critical role in inflammation or pancreatic endocrine activity. Overall, our results underscore the emerging role of DNA methylation as a key modulator of disease severity in CF.
SN - 1868-7075
SN - 1868-7083
ER -